Table 3.
Upstream inhibition regulators of differential expressed genes between granulosa cell-rich and-poor follicles
| Upstream regulator | Molecule type | Predicted activation state | Activation z score | P value of overlap | Target molecules in dataset |
|---|---|---|---|---|---|
| PD98059 | Chemical-kinase inhibitor | Inhibited | − 2.63 | 3.35.E−03 | ATP6V1B1, CCND2, CD83, COL1A2, C |
| OL3A1, CTSL, MMP1, MT3, TUB4A | |||||
| Cycloheximide | Chemical reagent | Inhibited | − 2.49 | 4.10.E−03 | ASS1, CYP19A1, ERG, GBP1, IGFBP4, IG |
| FBP5, MMP1 | |||||
| Cholesterol | Chemical-endogenous mammalian | Inhibited | − 2.43 | 1.14.E−03 | CD5L, COL3A1, CYBB, FLT1, LYZ, MMP1 |
| Tgf beta | Group | Inhibited | − 2.41 | 2.14.E−03 | BAMBI, CCND2, COL1A2, IGFBP5, MMP1, NOX4 |
| Doxorubicin | Chemical drug | Inhibited | − 2.22 | 6.90.E−02 | A2M, COL3A1, CYBB, IGFBP7, NOX4 |
| Actinomycin D | Chemical drug | Inhibited | − 2.12 | 9.73.E−03 | ASS1, COL1A2, IGFBP4, IGFBP5, MAT1A |
| H89 | Chemical-kinase inhibitor | − 1.98 | 6.97.E−03 | CD83, CYP19A1, IGFBP5, MMP1 | |
| Cisplatin | Chemical drug | − 1.96 | 3.15.E−01 | A2M, FLT1, LYZ, MAT1A, NOX4 | |
| N-Nitro-L-arginine methyl | Chemical drug | − 1.95 | 1.33.E−04 | ACTA1, CD83, COL1A2, COL3A1, CYBB | |
| NFKBIA | Transcription regulator | − 1.94 | 1.05.E−02 | A2M, ATP6V1B1, CCND2, CHI3L1, CO L1A2, COL3A1, MMP1 |